Literature DB >> 23535834

The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.

M Lagière1, S Navailles, L Mignon, A Roumegous, M-F Chesselet, P De Deurwaerdère.   

Abstract

Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23535834     DOI: 10.1007/s00221-013-3478-4

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  51 in total

1.  Serotonin modulates pallidal neuronal activity in the awake monkey.

Authors:  Hitoshi Kita; Satomi Chiken; Yoshihisa Tachibana; Atsushi Nambu
Journal:  J Neurosci       Date:  2007-01-03       Impact factor: 6.167

Review 2.  Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.

Authors:  T N Chase; T M Engber; M M Mouradian
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

3.  Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia.

Authors:  A Beyeler; N Kadiri; S Navailles; M Ben Boujema; F Gonon; C Le Moine; C Gross; P De Deurwaerdère
Journal:  Neuroscience       Date:  2010-05-04       Impact factor: 3.590

4.  Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats.

Authors:  L Gong; R M Kostrzewa
Journal:  Pharmacol Biochem Behav       Date:  1992-03       Impact factor: 3.533

5.  Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons.

Authors:  A Mehta; K Eberle-Wang; M F Chesselet
Journal:  Pharmacol Biochem Behav       Date:  2001-02       Impact factor: 3.533

Review 6.  Posteroventral medial pallidotomy in Parkinson's disease.

Authors:  A E Lang; J Duff; J A Saint-Cyr; L Trepanier; R E Gross; W Lombardi; E Montgomery; W Hutchinson; A M Lozano
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

Review 7.  Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system.

Authors:  Małgorzata Filip; Michael Bader
Journal:  Pharmacol Rep       Date:  2009 Sep-Oct       Impact factor: 3.024

8.  Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

Authors:  Philippe De Deurwaerdère; Sylvia Navailles; Kelly A Berg; William P Clarke; Umberto Spampinato
Journal:  J Neurosci       Date:  2004-03-31       Impact factor: 6.167

9.  Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Authors:  Sylvia Navailles; Bernard Bioulac; Christian Gross; Philippe De Deurwaerdère
Journal:  Neurobiol Dis       Date:  2010-01-22       Impact factor: 5.996

10.  Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.

Authors:  Huma Ikram; Noreen Samad; Darakhshan Jabeen Haleem
Journal:  Pak J Pharm Sci       Date:  2007-07       Impact factor: 0.684

View more
  6 in total

Review 1.  Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

Authors:  P De Deurwaerdère; M Lagière; M Bosc; S Navailles
Journal:  Exp Brain Res       Date:  2013-04-25       Impact factor: 1.972

2.  Role of 5-HT2C receptors in the enhancement of c-Fos expression induced by a 5-HT2B/2C inverse agonist and 5-HT 2 agonists in the rat basal ganglia.

Authors:  S Navailles; M Lagière; C Le Moine; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-05-17       Impact factor: 1.972

3.  Lateral Habenula 5-HT2C Receptor Function Is Altered by Acute and Chronic Nicotine Exposures.

Authors:  Cristiano Bombardi; Francis Delicata; Claudio Tagliavia; Annamaria Grandis; Massimo Pierucci; Antonella Marino Gammazza; Maurizio Casarrubea; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 4.  Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.

Authors:  Cristina Miguelez; Teresa Morera-Herreras; Maria Torrecilla; Jose A Ruiz-Ortega; Luisa Ugedo
Journal:  Front Neural Circuits       Date:  2014-03-17       Impact factor: 3.492

5.  Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation.

Authors:  Sergio Vegas-Suárez; Teresa Morera-Herreras; Catalina Requejo; José Vicente Lafuente; Rosario Moratalla; Cristina Miguélez; Luisa Ugedo
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

6.  A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT2C Receptors in Rats: Implication of the Subthalamic Nucleus.

Authors:  Mélanie Lagière; Marion Bosc; Sara Whitestone; Abdelhamid Benazzouz; Abdeslam Chagraoui; Mark J Millan; Philippe De Deurwaerdère
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.